Global Blood Therapeutics, Inc. (GBT) confirmed that the FDA has approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease in adults and children 12 years of age and older. According to the company press release, Oxbryta is the "first and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy."
Earlier, the company presented updates on corporate developments on 10/8/2019 at its Analyst & Investor Day. Global Blood is a clinical-stage biopharmaceutical company having expertise in blood biology and structural and medicinal chemistry. The company's lead product candidate is